RE:EU approves first I/O combinationJanuary 16, 2024 -
Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types
https://www.biospace.com/article/releases/halozyme-announces-roche-receives-european-commission-approval-of-tecentriq-sc-with-enhanze-representing-the-eu-s-first-subcutaneous-pd-l-1-cancer-immunotherapy-for-multiple-cancer-types/